A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT
Completed · Phase 1
Conditions studied: Hematologic Malignancies
In brief
This is a phase trial to determine the maximum tolerated dose (MTD) of clofarabine in a combination with a myeloablative dose of busulfan. This is an initial step in developing a novel myeloablative preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT). While this phase I trial will initially develop the regimen in patients with refractory disease, it is expected that it will find its best application in patients with less advanced disease
Key facts
- Study ID
- NCT00477542
- Run by
- Indiana University
- People needed
- 18
- Starts
- 2007-05-01
- Expected to finish
- 2010-11-01
- Last updated by the study team
- 2014-09-18
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Documentation of disease. Patients must have one of the following disease types:
- Acute myeloid leukemia (AML) with either:
- Primary refractory to induction chemotherapy
- Relapsed and refractory AML with >5% blasts in bone marrow or extramedullary disease (excluding active disease of the central nervous system).
- Patients in second or subsequent complete remission (CR2, CR3, etc.).
- Acute lymphoblastic leukemia (ALL) with one of the following criteria:
- Primary refractory to induction chemotherapy.
- Relapsed and refractory ALL with >5% blasts in bone marrow or extramedullary disease (excluding active disease of the central nervous system).
- Patients in second or subsequent complete remission (CR2, CR3, etc.).
- Myelodysplasia, refractory anemia with excess blasts with 11-20% blasts in the bone marrow (RAEB II).
- Chronic myelogenous leukemia (CML) with one of the following criteria:
- Accelerated phase.
- Patients in blast crisis.
- Patients with aggressive non-Hodgkin's lymphoma (NHL), including diffuse large cell lymphoma, mediastinal B-cell lymphoma, transformed lymphoma, mantle cell lymphoma, and peripheral T cell lymphoma, who also have one of the following criteria:
- Failure to achieve complete remission to primary induction therapy
- Relapsed NHL, refractory to at least one line of salvage systemic therapy
- Patients who relapse < 6 months following autologous stem cell transplantation are not eligible.
- Patient age 18-60 years
- Availability of a consenting HLA-matched donor
- Performance status ECOG 0-1
- No active infection. Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection.
- No HIV disease. Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies.
- Non-pregnant and non-nursing. Treatment under this protocol would expose a fetus to significant risks. Women of childbearing potential should have a negative pregnancy test prior to study entry. Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Appropriate methods of birth control include oral contraceptives, implantable hormonal contraceptives (Norplant®), or double barrier method (diaphragm plus condom).
- Required baseline laboratory values:
- LVEF > 45% corrected
You may not qualify if…
- Patients who relapse < 6 months following autologous stem cell transplantation are not eligible
Where it is running
- Indiana University Cancer Center — Indianapolis, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.